Compounded Bioidentical Hormone Therapy Market size is expected to register around 5.2% CAGR during the forecast period i.e., between 2024-2036. The compounded bioidentical hormone therapy utilizes processed hormones to help people in regulating the hormonal imbalances. It is estimated that around 80% women suffer from hormonal imbalance worldwide. The global compounded bioidentical hormone market is estimated to expand at a rapid rate over the forecast period on account of the increasing population of women with hormonal imbalances. Furthermore, compounded bioidentical hormone therapy can be used to treat conditions, such as, thyroid disorders, insulin resistance, osteoporosis, and fibromyalgia. As the number of patients is increasing worldwide, scientists are expeditiously researching the remedies, such as, bioidentical hormones. Additionally, menopause in women causes night sweats, insomnia, and hot flashes, which can be prevented by using compounded bioidentical hormone therapy. Owing to its various benefits, the global market is estimated to boost over the forecast period.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
5.2% |
|
Regional Scope |
|
The market is segmented by type into estrogen, progesterone, and testosterone, out of which, the estrogen segment is anticipated to hold the notable share in the compounded bioidentical hormone therapy market on account of growing number of women using bioidentical hormone therapy to balance their estrogen levels. The bioidentical hormone therapy helps women in reducing the adverse effects of menopause, which is the reason the global market is predicted to grow over the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Product Type |
|
|
By End-Use |
|
Regionally, the global compounded bioidentical hormone therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The global market in the North America industry is estimated to account for largest revenue share by 2036, on the back of higher healthcare expenditure, increasing thyroid prevalence amongst women, and more awareness amongst the people. According to a report by American Thyroid Association, one in eight women will develop a thyroid disorder during her lifetime. Furthermore, scientists are proactive to find out remedies for menopause-related issues, which is the reason the global compounded bioidentical hormone therapy is expected to propel over the forecast period.
The Europe region is also projected to witness considerable growth in the compounded bioidentical hormone therapy market over the forecast period owing to the higher disposable income of people, and robust healthcare infrastructure.
April 14, 2022: Therapeutics MD finalises the divestiture of vitaCare prescription services through USD 150 million cash transaction to focus solely on its women’s health portfolio.
September 26, 2018: The U.S. Food and Drug Administration announced an agreement with the National Academies of Science, Engineering and Medicine (NASEM) for conducting research examining the clinical use of compounded bioidentical hormonal replacement therapy (BHRT).
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?